Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD)

Margaret M McGovern, Ruzan Avetisyan, Bernd-Jan Sanson, Olivier Lidove, Margaret M McGovern, Ruzan Avetisyan, Bernd-Jan Sanson, Olivier Lidove

Abstract

Acid sphingomyelinase deficiency (ASMD), a rare lysosomal storage disease, is an autosomal recessive genetic disorder caused by different SMPD1 mutations. Historically, ASMD has been classified as Niemann-Pick disease (NPD) types A (NPD A) and B (NPD B). NPD A is associated with a uniformly devastating disease course, with rapidly progressing psychomotor degeneration, leading to death typically by the age of 3 years, most often from respiratory failure. In contrast, the clinical phenotype and life expectancy of patients with NPD B may vary widely. Almost all patients have hepatosplenomegaly and an atherogenic lipid profile, and most patients have interstitial lung disease with progressive impairment of pulmonary function and hematologic abnormalities including cytopenias. Other common clinical manifestations include liver dysfunction, heart disease, skeletal abnormalities and growth delays. Some patients with ASMD who survive beyond early childhood have intermediate phenotypes (variant NPD B) characterized by combinations of non-neurologic and mild to severe neurologic symptoms. The physical and psychosocial burden of illness in patients with NPD B is substantial. Common symptoms include shortness of breath, joint or limb pain, abdominal pain, bleeding and bruising. The disease often leads to chronic fatigue, limited physical or social activity and difficulties in performing daily activities or work. Many patients die before or in early adulthood, often from pneumonia/respiratory failure or liver failure. Available treatments are limited to symptom management and supportive care. An enzyme replacement therapy currently in clinical development is expected to be the first treatment addressing the underlying pathology of the disease. Early diagnosis and appropriate management are essential for reducing the risk of complications. While knowledge about ASMD is evolving, more evidence about ASMD and the natural history across the disease spectrum is needed, to improve disease recognition, timely diagnosis and appropriate disease management.

Keywords: ASMD; Acid sphingomyelinase deficiency; Burden of illness; Disease manifestations; Lysosomal storage disorder; Natural history; Niemann-Pick disease types A and B.

Figures

Fig. 1
Fig. 1
ASMD manifestations in patients with NPD B, in the currently published literature. ALT alanine amino transferases; ASMD acid sphingomyelinase deficiency; AST aspartate amino transferase; BMC bone mineral content; BMD bone mineral density; NPD Niemann-Pick disease

References

    1. Schuchman EH. The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. J Inherit Metab Dis. 2007;30:654–663. doi: 10.1007/s10545-007-0632-9.
    1. Schuchman EH, Wasserstein MP. Types A and B Niemann-Pick disease. Best Pract Res Clin Endocrinol Metab. 2015;29:237–247. doi: 10.1016/j.beem.2014.10.002.
    1. McGovern MM, Aron A, Brodie SE, Desnick RJ, Wasserstein MP. Natural history of Type A Niemann-Pick disease: possible endpoints for therapeutic trials. Neurology. 2006;66:228–232. doi: 10.1212/01.wnl.0000194208.08904.0c.
    1. Hollak CE, de Sonnaville ES, Cassiman D, Linthorst GE, Groener JE, Morava E, et al. Acid sphingomyelinase (Asm) deficiency patients in The Netherlands and Belgium: disease spectrum and natural course in attenuated patients. Mol Genet Metab. 2012;107:526–533. doi: 10.1016/j.ymgme.2012.06.015.
    1. Wasserstein MP, Desnick RJ, Schuchman EH, Hossain S, Wallenstein S, Lamm C, McGovern MM. The natural history of type B Niemann-Pick disease: results from a 10-year longitudinal study. Pediatrics. 2004;114:e672–e677. doi: 10.1542/peds.2004-0887.
    1. Mihaylova V, Hantke J, Sinigerska I, Cherninkova S, Raicheva M, Bouwer S, et al. Highly variable neural involvement in sphingomyelinase-deficient Niemann–Pick disease caused by an ancestral Gypsy mutation. Brain. 2007;130:1050–1061. doi: 10.1093/brain/awm026.
    1. Pavlů-Pereira H, Asfaw B, Poupctová H, Ledvinová J, Sikora J, Vanier MT, et al. Acid sphingomyelinase deficiency. Phenotype variability with prevalence of intermediate phenotype in a series of twenty-five Czech and Slovak patients. A multi-approach study. J Inherit Metab Dis. 2005;28:203–227. doi: 10.1007/s10545-005-5671-5.
    1. Wasserstein MP, Aron A, Brodie SE, Simonaro C, Desnick RJ, McGovern MM. Acid sphingomyelinase deficiency: prevalence and characterization of an intermediate phenotype of Niemann-Pick disease. J Pediatr. 2006;149:554–559. doi: 10.1016/j.jpeds.2006.06.034.
    1. Pastores GM, Hughes DA. Non-neuronopathic lysosomal storage disorders: disease spectrum and treatments. Best Pract Res Clin Endocrinol Metab. 2015;29:173–182. doi: 10.1016/j.beem.2014.08.005.
    1. Vanier MT. Prenatal diagnosis of Niemann-Pick diseases types A, B and C. Prenat Diagn. 2002;22:630–632. doi: 10.1002/pd.368.
    1. Vanier MT. Niemann-Pick diseases. Handb Clin Neurol. 2013;113:1717–1721. doi: 10.1016/B978-0-444-59565-2.00041-1.
    1. Schuchman EH, Desnick RJ. Niemann-Pick disease types A and B: acid sphingomyelinase deficiencies. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson KM, Mitchell G, editors. OMMBID-The online metabolic and molecular bases of inherited disease. New York: McGraw Hill; 2013.
    1. Simonaro CM, Desnick RJ, McGovern MM, Wasserstein MP, Schuchman EH. The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations. Am J Hum Genet. 2002;71:1413–1419. doi: 10.1086/345074.
    1. Pittis MG, Ricci V, Guerci VI, Marçais C, Ciana G, Dardis A, et al. Acid sphingomyelinase: identification of nine novel mutations among Italian Niemann Pick type B patients and characterization of in vivo functional in-frame start codon. Hum Mutat. 2004;24:186–187. doi: 10.1002/humu.9263.
    1. Ricci V, Stroppiano M, Corsolini F, Di Rocco M, Parenti G, Regis S, et al. Screening of 25 Italian patients with Niemann-Pick A reveals fourteen new mutations, one common and thirteen private, in SMPD1. Hum Mutat. 2004;24:105. doi: 10.1002/humu.9258.
    1. Ida H, Rennert OM, Maekawa K, Eto Y. Identification of three novel mutations in the acid sphinogomyelinase gene of Japanese patients with Niemann-Pick disease type A and B. Hum Mutat. 1996;7:65–67. doi: 10.1002/(SICI)1098-1004(1996)7:1<65::AID-HUMU10>;2-Q.
    1. Irun P, Mallén M, Dominguez C, Rodriguez-Sureda V, Alvarez-Sala LA, Arslan N, et al. Identification of seven novel SMPD1 mutations causing Niemann–Pick disease types A and B. Clin Genet. 2013;84:356–361. doi: 10.1111/cge.12076.
    1. Lan MY, Lin SJ, Chen YF, Peng CH, Liu YF. A novel missense mutation of the SMPD1 gene in a Taiwanese patient with type B Niemann-Pick disease. Ann Hematol. 2009;88:695–697. doi: 10.1007/s00277-008-0648-8.
    1. Rodríguez-Pascau L, Gort L, Schuchman EH, Vilageliu L, Grinberg D, Chabás A. Identification and characterization of SMPD1 mutations causing Niemann-Pick types A and B in Spanish patients. Hum Mutat. 2009;30:1117–1122. doi: 10.1002/humu.21018.
    1. Zhang H, Wang Y, Gong Z, Li X, Qiu W, Han L, et al. Identification of a distinct mutation spectrum in the SMPD1 gene of Chinese patients with acid sphingomyelinase-deficient Niemann-Pick disease. Orphanet J Rare Dis. 2013;8:15. doi: 10.1186/1750-1172-8-15.
    1. Rhein C, Muhle C, Kornhuber J, Reichel M. Alleged detrimental mutations in the SMPD1 gene in patients with Niemann-Pick disease. Int J Mol Sci. 2015;16:13649–13652. doi: 10.3390/ijms160613649.
    1. Kingma SD, Bodamer OA, Wijburg FA. Epidemiology and diagnosis of lysosomal storage disorders; challenges of screening. Best Pract Res Clin Endocrinol Metab. 2015;29:145–157. doi: 10.1016/j.beem.2014.08.004.
    1. . Prevalence of rare diseases: Bibliographic data. Orphanet Report Series, Rare Diseases collection, Number 1: Diseases in alphabetical order. 2016. . Accessed 5 May 2015.
    1. Acuña M, Martínez P, Moraga C, He X, Moraga M, Hunter B, et al. Epidemiological, clinical and biochemical characterization of the p. (Ala359Asp) SMPD1 variant causing Niemann-Pick disease type B. Eur J Hum Genet. 2015;24:208–213. doi: 10.1038/ejhg.2015.89.
    1. Leavitt JA, Kotagal S. The “cherry red” spot. Pediatr Neurol. 2007;37:74–75. doi: 10.1016/j.pediatrneurol.2007.04.011.
    1. Ospina LH, Lyons CJ, McCormick AQ. “Cherry-red spot” or “perifoveal white patch”? Can J Ophthalmol. 2005;40:609–610. doi: 10.1016/S0008-4182(05)80054-7.
    1. Mechtler TP, Metz TF, Müller HG, Ostermann K, Ratschmann R, De Jesus VR, et al. Short-incubation mass spectrometry assay for lysosomal storage disorders in newborn and high-risk population screening. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;908:9–17. doi: 10.1016/j.jchromb.2012.09.012.
    1. Mechtler TP, Stary S, Metz TF, De Jesús VR, Greber-Platzer S, Pollak A, et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet. 2012;379:335–341. doi: 10.1016/S0140-6736(11)61266-X.
    1. ACOG Committee on Genetics ACOG committee opinion No. 442: preconception and prenatal carrier screening for genetic diseases in individuals of eastern European Jewish descent. Obstet Gynecol. 2009;114:950–953. doi: 10.1097/AOG.0b013e3181bd12f4.
    1. McGovern MM, Dionisi-Vici C, Giugliani R, Hwu P, Lidove O, Lukacs Z, et al. Consensus Recommendation on a Diagnostic Guideline for Acid Sphingomyelinase Deficiency. Genet Med. 2017. [accepted for publication].
    1. Cassiman D, Packman S, Bembi B, Turkia HB, Al-Sayed M, Schiff M, et al. Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (Niemann-Pick disease type B and B variant): literature review and report of new cases. Mol Genet Metab. 2016;118:206–3. doi: 10.1016/j.ymgme.2016.05.001.
    1. McGovern MM, Lippa N, Bagiella E, Schuchman EH, Desnick RJ, Wasserstein MP. Morbidity and mortality in type B Niemann-Pick disease. Genet Med. 2013;15:618–623. doi: 10.1038/gim.2013.4.
    1. Wasserstein M, Godbold J, McGovern MM. Skeletal manifestations in pediatric and adult patients with Niemann Pick disease type B. J Inherit Metab Dis. 2013;36:123–127. doi: 10.1007/s10545-012-9503-0.
    1. Thurberg BL, Wasserstein MP, Schiano T, O’Brien F, Richards S, Cox GF, McGovern MM. Liver and skin histopathology in adults with acid sphingomyelinase deficiency (Niemann-Pick disease type B) Am J Surg Pathol. 2012;36:1234–1246. doi: 10.1097/PAS.0b013e31825793ff.
    1. Henderson SL, Packman W, Packman S. Psychosocial aspects of patients with Niemann-Pick disease, type B. Am J Med Genet A. 2009;149A:2430–2436. doi: 10.1002/ajmg.a.33077.
    1. McGovern MM, Wasserstein MP, Giugliani R, Bembi B, Vanier MT, Mengel E, et al. A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B. Pediatrics. 2008;122:e341–e349. doi: 10.1542/peds.2007-3016.
    1. Guillemot N, Troadec C, de Villemeur TB, Clément A, Fauroux B. Lung disease in Niemann-Pick disease. Pediatr Pulmonol. 2007;42:1207–1214. doi: 10.1002/ppul.20725.
    1. Mendelson DS, Wasserstein MP, Desnick RJ, Glass R, Simpson W, Skloot G, et al. Type B Niemann-Pick disease: findings at chest radiography, thin-section CT, and pulmonary function testing. Radiology. 2006;238:339–345. doi: 10.1148/radiol.2381041696.
    1. McGovern MM, Pohl-Worgall T, Deckelbaum RJ, Simpson W, Mendelson D, Desnick RJ, et al. Lipid abnormalities in children with types A and B Niemann Pick disease. J Pediatr. 2004;145:77–81. doi: 10.1016/j.jpeds.2004.02.048.
    1. McGovern MM, Wasserstein MP, Aron A, Desnick RJ, Schuchman EH, Brodie SE. Ocular manifestations of Niemann-Pick disease type B. Ophthalmology. 2004;111:1424–1427. doi: 10.1016/j.ophtha.2003.10.034.
    1. Lidove O, Sedel F, Charlotte F, Froissart R, Vanier MT. Cirrhosis and liver failure: expanding phenotype of acid sphingomyelinase-deficient Niemann-Pick disease in adulthood. JIMD Rep. 2015;15:117–121.
    1. Elleder M, Cihula J. Niemann-Pick disease (variation in the sphingomyelinase deficient group). Neurovisceral phenotype (A) with an abnormally protracted clinical course and variable expression of neurological symptomatology in three siblings. Eur J Pediatr. 1983;140:323–328. doi: 10.1007/BF00442673.
    1. Sogawa H, Horino K, Nakamura F, Kudoh T, Oyanagi K, Yamanouchi T, et al. Chronic Niemann-Pick disease with sphingomyelinase deficiency in two brothers with mental retardation. Eur J Pediatr. 1978;128:235–240. doi: 10.1007/BF00445608.
    1. Gan-Or Z, Orr-Urtreger A, Alcalay RN, Bressman S, Giladi N, Rouleau GA. The emerging role of SMPD1 mutations in Parkinson’s disease: implications for future studies. Parkinsonism Relat Disord. 2015;21:1294–1295. doi: 10.1016/j.parkreldis.2015.08.018.
    1. Lidove O, Belmatoug N, Froissart R. Acid sphingomyelinase deficiency (Niemann-Pick disease type B) in adulthood: A retrospective multicentric study of 28 adult cases. Rev Med Intern. 2016. [in press].
    1. Zampieri S, Filocamo M, Pianta A, Lualdi S, Gort L, Coll MJ, et al. SMPD1 mutation update: database and comprehensive analysis of published and novel variants. Hum Mutat. 2015;37:139–147. doi: 10.1002/humu.22923.
    1. Simonaro CM, Park JH, Eliyahu E, Shtraizent N, McGovern MM, Schuchman EH. Imprinting at the SMPD1 locus: implications for acid sphingomyelinase-deficient Niemann-Pick disease. Am J Hum Genet. 2006;78:865–870. doi: 10.1086/503750.
    1. Levran O, Desnick RJ, Schuchman EH. Type A Niemann-Pick disease: a frameshift mutation in the acid sphingomyelinase gene (fsP330) occurs in Ashkenazi Jewish patients. Hum Mutat. 1993;2:317–319. doi: 10.1002/humu.1380020414.
    1. Levran O, Desnick RJ, Schuchman EH. Identification and expression of a common missense mutation (L302P) in the acid sphingomyelinase gene of Ashkenazi Jewish type A Niemann-Pick disease patients. Blood. 1992;80:2081–2087.
    1. Levran O, Desnick RJ, Schuchman EH. Niemann-Pick type B disease. Identification of a single codon deletion in the acid sphingomyelinase gene and genotype/phenotype correlations in type A and B patients. J Clin Invest. 1991;88:806–810. doi: 10.1172/JCI115380.
    1. Vanier MT, Ferlinz K, Rousson R, Duthel S, Louisot P, Sandhoff K, Suzuki K. Deletion of arginine (608) in acid sphingomyelinase is the prevalent mutation among Niemann-Pick disease type B patients from northern Africa. Hum Genet. 1993;92:325–330. doi: 10.1007/BF01247328.
    1. Gluck I, Zeigler M, Bargal R, Schiff E, Bach G. Niemann Pick Disease type A in Israeli Arabs: 677delT, a common novel single mutation. Mutations in brief no. 161. Online. Hum Mutat. 1998;12:136. doi: 10.1002/(SICI)1098-1004(1998)12:2<136::AID-HUMU12>;2-Y.
    1. National Niemann-Pick Disease Foundation . Niemann-Pick disease overview — types A, B and C. 2015.
    1. Lidove O, Le Fèvre L, Goasguen N, Jamali M, Vercellino L, Garnier M, et al. Acid sphingomyelinase deficiency and spleen trauma: splenectomy or not splenectomy? Rev Med Interne. 2015;36:619–622. doi: 10.1016/j.revmed.2014.10.367.
    1. Chen Z, Chen Z, Wu S, Wang X. Niemann-Pick disease resulting in spontaneous splenic rupture in an adult: report of a case. Surg Today. 2008;38:473–475. doi: 10.1007/s00595-007-3641-2.
    1. Simões RG, Maia H. Niemann-Pick type B in adulthood. BMJ Case Rep. 2015;2015.
    1. Wasserstein MP, Larkin AE, Glass RB, Schuchman EH, Desnick RJ, McGovern MM. Growth restriction in children with type B Niemann-Pick disease. J Pediatr. 2003;142:424–428. doi: 10.1067/mpd.2003.113.
    1. Parenti G, Andria G, Ballabio A. Lysosomal storage diseases: from pathophysiology to therapy. Annu Rev Med. 2015;66:471–486. doi: 10.1146/annurev-med-122313-085916.
    1. Wasserstein MP, Jones SA, Soran H, Diaz GA, Lippa N, Thurberg BL, et al. Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency. Mol Genet Metab. 2015;116:88–97. doi: 10.1016/j.ymgme.2015.05.013.
    1. Identifier: NCT02004691. Efficacy, safety, pharmacodynamic, and pharmacokinetics study of olipudase alfa in patients with acid sphingomyelinase deficiency (ASCEND). 2016. . Accessed 23 May 2016.
    1. EudraCT Number 2015–000371-26. A phase 2/3, multicenter, randomized, double-blinded, placebo-controlled, repeat dose study to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of olipudase alfa in patients with acid sphingomyelinase deficiency. = +2015-000371-26+. Accessed 23 May 2016.
    1. EudraCT Number 2014–003198-40. A phase 1/2, multi-center, open-label, ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of olipudase alfa in pediatric patients aged <18 years with acid sphingomyelinase deficiency. +. Accessed 23 May 2016.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다